SI2459220T1 - Biorazgradljivi v vodi netopni hidrogeli na osnovi polietilenglikola - Google Patents

Biorazgradljivi v vodi netopni hidrogeli na osnovi polietilenglikola

Info

Publication number
SI2459220T1
SI2459220T1 SI201032040T SI201032040T SI2459220T1 SI 2459220 T1 SI2459220 T1 SI 2459220T1 SI 201032040 T SI201032040 T SI 201032040T SI 201032040 T SI201032040 T SI 201032040T SI 2459220 T1 SI2459220 T1 SI 2459220T1
Authority
SI
Slovenia
Prior art keywords
polyethylene glycol
based water
glycol based
biodegradable polyethylene
insoluble hydrogels
Prior art date
Application number
SI201032040T
Other languages
English (en)
Inventor
Harald Rau
Ulrich Hersel
Mathias Krusch
Dirk Vetter
Tobias Voigt
Original Assignee
Ascendis Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma A/S filed Critical Ascendis Pharma A/S
Publication of SI2459220T1 publication Critical patent/SI2459220T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00Processes of treating or compounding macromolecular substances
    • C08J3/02Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075Macromolecular gels
SI201032040T 2009-07-31 2010-07-30 Biorazgradljivi v vodi netopni hidrogeli na osnovi polietilenglikola SI2459220T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09167026 2009-07-31
EP09172339 2009-10-06
PCT/EP2010/061155 WO2011012715A1 (en) 2009-07-31 2010-07-30 Biodegradable polyethylene glycol based water-insoluble hydrogels
EP10737075.1A EP2459220B1 (en) 2009-07-31 2010-07-30 Biodegradable polyethylene glycol based water-insoluble hydrogels

Publications (1)

Publication Number Publication Date
SI2459220T1 true SI2459220T1 (sl) 2020-12-31

Family

ID=43027631

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201032040T SI2459220T1 (sl) 2009-07-31 2010-07-30 Biorazgradljivi v vodi netopni hidrogeli na osnovi polietilenglikola

Country Status (23)

Country Link
US (1) US11559482B2 (sl)
EP (2) EP3782649A1 (sl)
JP (1) JP5904941B2 (sl)
KR (1) KR101770844B1 (sl)
CN (1) CN102573913B (sl)
AU (1) AU2010277556B2 (sl)
BR (1) BR112012002280B1 (sl)
CA (1) CA2769162C (sl)
ES (1) ES2833035T3 (sl)
HK (1) HK1173082A1 (sl)
HR (1) HRP20201609T1 (sl)
HU (1) HUE052816T2 (sl)
IL (1) IL217743A (sl)
LT (1) LT2459220T (sl)
MX (1) MX343925B (sl)
MY (1) MY156872A (sl)
NZ (1) NZ597960A (sl)
PL (1) PL2459220T3 (sl)
RU (1) RU2554854C9 (sl)
SG (1) SG177761A1 (sl)
SI (1) SI2459220T1 (sl)
WO (1) WO2011012715A1 (sl)
ZA (1) ZA201200686B (sl)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5732053B2 (ja) 2009-07-31 2015-06-10 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 持続型インスリン組成物
JP5738291B2 (ja) * 2009-07-31 2015-06-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリンリンカー複合体を含むプロドラッグ
CA2776723C (en) 2009-10-29 2018-09-25 Ascendis Pharma As Sterilization of biodegradable hydrogels
CA2783296C (en) 2009-12-15 2019-01-15 Ascendis Pharma As Growth hormone composition
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
EP2525829A1 (en) 2010-01-22 2012-11-28 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
WO2011089216A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
US9518087B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
US10451897B2 (en) 2011-03-18 2019-10-22 Johnson & Johnson Vision Care, Inc. Components with multiple energization elements for biomedical devices
EP2704695A1 (en) * 2011-05-03 2014-03-12 Telik, Inc. Excipient compatibility with ezatiostat
US11123364B2 (en) * 2011-06-21 2021-09-21 Bvw Holding Ag Medical device comprising boswellic acid
BR112014003225A2 (pt) 2011-08-12 2017-03-01 Ascendis Pharma As profármacos de treprostinil ligados a veículo
WO2013024053A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
EP2741738A1 (en) * 2011-08-12 2014-06-18 Ascendis Pharma A/S Sustained release composition of prostacyclin
SG11201400815TA (en) 2011-10-12 2014-09-26 Ascendis Pharma Ophthalmology Division As Prevention and treatment of ocular conditions
JP6051223B2 (ja) * 2011-11-03 2016-12-27 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH ペプチドの放出可能な結合のためのチロシンに基づくリンカー
US8857983B2 (en) 2012-01-26 2014-10-14 Johnson & Johnson Vision Care, Inc. Ophthalmic lens assembly having an integrated antenna structure
US20150087688A1 (en) 2012-04-25 2015-03-26 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
US20140073589A1 (en) * 2012-06-27 2014-03-13 Shire Ag Amphetamine Prodrugs
EP2888234B1 (en) 2012-08-21 2017-12-06 Janssen Pharmaceutica NV Haptens of aripiprazole and their use in immunoassays
WO2014031595A1 (en) * 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of paliperidone
CN104736561B (zh) 2012-08-21 2018-06-12 詹森药业有限公司 帕潘立酮的抗体及其用途
PL2888593T3 (pl) 2012-08-21 2019-02-28 Janssen Pharmaceutica Nv Przeciwciała przeciwko rysperydonowi i ich zastosowanie
PL3354751T3 (pl) 2012-08-21 2020-03-31 Janssen Pharmaceutica Nv Przeciwciała dla arypiprazolu i ich zastosowanie
CN104736567B (zh) 2012-08-21 2019-09-03 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス,インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
CN104736565B (zh) 2012-08-21 2019-03-12 詹森药业有限公司 利培酮半抗原的抗体及其用途
MX363462B (es) 2012-10-11 2019-03-25 Ascendis Pharma As Diagnostico, prevencion y tratamiento de enfermedades de la articulacion.
SG11201501914XA (en) * 2012-10-11 2015-05-28 Ascendis Pharma Ophthalmology Division As Vegf neutralizing prodrugs for the treatment of ocular conditions
RU2647729C2 (ru) * 2012-10-11 2018-03-19 Асцендис Фарма Ас Пролекарства на основе гидрогеля
EP2928501B1 (en) 2012-12-07 2020-05-06 Ascendis Pharma A/S Carrier-linked prostanoid prodrugs
US20140271885A1 (en) * 2013-03-15 2014-09-18 Intezyne Technologies, Inc. Copolymers for stable micelle formulations
DK2988732T3 (da) * 2013-04-22 2023-06-26 Ascendis Pharma As Modificerede hydrogeler
WO2014173759A1 (en) 2013-04-22 2014-10-30 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing modified drugs
CN105611914B (zh) 2013-06-19 2020-09-08 加利福尼亚大学董事会 局部递送治疗剂的化学构造物
RU2543375C1 (ru) * 2013-07-29 2015-02-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный университет" Комплексное соединение производного метилурацила с органической кислотой и способ его получения
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
ES2721098T3 (es) 2013-10-01 2019-07-26 Glaxosmithkline Ip Dev Ltd Compuestos para cromatografía de afinidad
CA2924661A1 (en) * 2013-10-08 2015-04-16 Ascendis Pharma Osteoarthritis Division A/S Hydrogel-linked il-1ra prodrug
CN103554296B (zh) * 2013-10-12 2015-09-16 天津大学 一种亚油酸改性葡聚糖及制备高分子脂质体的方法
US20160296600A1 (en) 2013-11-11 2016-10-13 Ascendis Pharma Relaxin Division A/S Relaxin Prodrugs
US9675607B2 (en) * 2013-11-13 2017-06-13 Northwestern University Epimorphic regeneration and related hydrogel delivery systems
CN103706233A (zh) * 2013-12-17 2014-04-09 杨亮月 一种环氧乙烷零排放处理体系及方法
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
BR112016019274A2 (pt) 2014-02-21 2017-10-10 Anokion Sa agentes terapêuticos glico-orientados
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
AU2015229014B2 (en) 2014-03-14 2019-07-25 The Regents Of The University Of California TCO conjugates and methods for delivery of therapeutic agents
CN106714854B (zh) 2014-07-17 2020-09-04 加利福尼亚大学董事会 用于生物医学应用的可控的自退火微凝胶颗粒
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
CA2955569C (en) 2014-08-06 2023-02-14 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
US10361404B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Anodes for use in biocompatible energization elements
US10361405B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes
US9793536B2 (en) 2014-08-21 2017-10-17 Johnson & Johnson Vision Care, Inc. Pellet form cathode for use in a biocompatible battery
US10381687B2 (en) 2014-08-21 2019-08-13 Johnson & Johnson Vision Care, Inc. Methods of forming biocompatible rechargable energization elements for biomedical devices
US9383593B2 (en) 2014-08-21 2016-07-05 Johnson & Johnson Vision Care, Inc. Methods to form biocompatible energization elements for biomedical devices comprising laminates and placed separators
US9715130B2 (en) 2014-08-21 2017-07-25 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form separators for biocompatible energization elements for biomedical devices
US10627651B2 (en) 2014-08-21 2020-04-21 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization primary elements for biomedical devices with electroless sealing layers
US9941547B2 (en) 2014-08-21 2018-04-10 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes and cavity structures
US9923177B2 (en) * 2014-08-21 2018-03-20 Johnson & Johnson Vision Care, Inc. Biocompatibility of biomedical energization elements
US9599842B2 (en) 2014-08-21 2017-03-21 Johnson & Johnson Vision Care, Inc. Device and methods for sealing and encapsulation for biocompatible energization elements
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
JP6723509B2 (ja) 2014-10-24 2020-07-15 日油株式会社 環状ベンジリデンアセタールリンカーを有する抗体―薬物複合体
US11298427B2 (en) 2015-05-29 2022-04-12 Ascendis Pharma A/S Prodrugs comprising a pyroglutamate linker
JP6959912B2 (ja) 2015-09-23 2021-11-05 ジェネンテック, インコーポレイテッド 抗vegf抗体の最適化変異体
US11458041B2 (en) * 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
US10155063B2 (en) 2015-11-12 2018-12-18 University Of Virginia Patent Foundation Methods for vas-occlusive contraception and reversal thereof
WO2017106501A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
CN108697640A (zh) * 2015-12-18 2018-10-23 韩捷 一种可在生理条件下降解的水凝胶
US10413616B2 (en) 2015-12-23 2019-09-17 Viking Scientific, Inc. Hydrogel prodrug for treatment
WO2017142879A1 (en) 2016-02-16 2017-08-24 The Regents Of The University Of California Methods for immune system modulation with microporous annealed particle gels
US10345620B2 (en) 2016-02-18 2019-07-09 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization elements incorporating fuel cells for biomedical devices
KR20230015517A (ko) 2016-03-01 2023-01-31 아센디스 파마 본 디지즈 에이/에스 Pth 프로드럭
US10842743B2 (en) 2016-04-08 2020-11-24 The Regents Of The University Of California Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents
CN105963792B (zh) * 2016-04-29 2019-03-22 深圳迈普再生医学科技有限公司 医用水凝胶组合物,医用水凝胶及其制备方法与应用
AU2017295938C1 (en) 2016-07-13 2021-10-07 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
MX2019003182A (es) 2016-09-29 2019-08-05 Ascendis Pharma Bone Diseases As Compuestos de hormona paratiroidea con bajas relaciones pico - valle.
BR112019005351A2 (pt) 2016-09-29 2019-06-11 Ascendis Pharma Growth Disorders As terapia combinada com agonistas de cnp de liberação controlada
JP7039574B2 (ja) 2016-09-29 2022-03-22 アセンディス ファーマ ボーン ディジージズ エー/エス 放出制御pth化合物の漸増用量設定
IL265591B2 (en) 2016-09-29 2023-12-01 Ascendis Pharma Bone Diseases As Dosing regimen for a controlled-release PTH compound
EP3562523A4 (en) 2016-12-29 2020-09-30 Tempo Therapeutics, Inc. PROCESSES AND SYSTEMS FOR THE TREATMENT OF A MEDICAL IMPLANT SITE
CA3055908A1 (en) 2017-03-10 2018-09-13 University Of Louisville Research Foundation, Inc. Fasl-engineered biomaterials with immunomodulatory function
KR20200007776A (ko) 2017-03-22 2020-01-22 제넨테크, 인크. 히드로겔 가교된 히알루론산 전구약물 조성물 및 방법
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN108864258A (zh) * 2017-05-12 2018-11-23 北京康明海慧生物科技有限公司 具有抑制肿瘤功能的peg化多肽及其制备方法与应用
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
CN107583104B (zh) * 2017-10-31 2020-12-01 无锡中科光远生物材料有限公司 一种可注射的用于脊柱修复的凝胶材料
KR20200083985A (ko) * 2017-11-02 2020-07-09 타르시어스 파마 리미티드 안구 염증을 치료하기 위한 포스포릴콜린-터프트신 접합체
CN107880288A (zh) * 2017-11-29 2018-04-06 桂林华诺威生物科技有限公司 一种透明质酸钠凝胶的制备方法
CN108096630B (zh) * 2018-01-29 2020-09-04 暨南大学 一种载淫羊藿苷和去铁胺的聚乳酸基骨组织支架及制备方法和应用
FR3079421A1 (fr) * 2018-03-28 2019-10-04 Edix Sa Presentations injectables, seringues et compositions a liberation prolongee et/ou controlee de lanreotide
JP2021519336A (ja) 2018-03-28 2021-08-10 アセンディス ファーマ オンコロジー ディヴィジョン エー/エス Il−2コンジュゲート
CN110865130B (zh) * 2018-08-27 2023-08-22 北京海晶生物医药科技有限公司 一种盐酸奥洛他定及其有关物质的检测方法
US20210330807A1 (en) 2018-09-26 2021-10-28 Ascendis Pharma A/S Novel hydrogel conjugates
TW202027794A (zh) * 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣3多肽之持續遞送
CN111077235B (zh) * 2018-10-19 2023-09-08 重庆医药工业研究院有限责任公司 一种测定2-[(2-甲基-5-溴苯基)甲基]-5-(4-氟苯基)噻吩杂质的方法
WO2020141221A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Conjugates of pattern recognition receptor agonists
US20220054478A1 (en) 2019-01-04 2022-02-24 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
MX2021007707A (es) 2019-01-04 2021-08-05 Ascendis Pharma Oncology Div A/S Niveles de farmacos locales sostenidos para los agonistas inmunitarios innatos.
CA3125488A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
CN113924122A (zh) * 2019-06-07 2022-01-11 立卡达有限责任公司 水凝胶微粒中的可调降解
WO2020254609A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Tyrosine kinase inhibitor conjugates
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
CA3143279A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 conjugates
WO2020254602A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma A/S Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
CA3143442A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma A/S Conjugates of heteroaromatic nitrogen-comprising compounds
CN114026080A (zh) 2019-06-21 2022-02-08 阿森迪斯药物股份有限公司 含有提供π-电子对的杂芳族氮的化合物的缀合物
PE20220902A1 (es) * 2019-06-26 2022-05-30 Biorchestra Co Ltd Nanoparticulas micelares y sus usos
WO2021000050A1 (en) * 2019-07-03 2021-01-07 Molly Sandra Shoichet Hydrogel compositions and uses thereof
CN112168820B (zh) * 2019-07-05 2023-09-29 中国科学院生物物理研究所 SRCAP ATPase抑制剂在结直肠癌治疗中的应用
BR112022003689A2 (pt) * 2019-08-29 2022-05-24 Douglas Godfrin Paul Matriz de hidrogel
KR20220104718A (ko) * 2019-11-19 2022-07-26 루브리졸 어드밴스드 머티어리얼스, 인코포레이티드 비스비구아니드로 염화되는 폴리우레탄 조성물
MX2022007916A (es) 2020-01-03 2022-07-21 Ascendis Pharma As Conjugados que experimentan rearreglos intramoleculares.
CN111138293B (zh) * 2020-01-10 2023-07-07 蚌埠丰原医药科技发展有限公司 一种用微通道反应器合成富马酸伊布利特中间体的方法
WO2021158968A1 (en) 2020-02-06 2021-08-12 Ocular Therapeutix, Inc. Compositions and methods for treating ocular diseases
KR102375663B1 (ko) * 2020-03-24 2022-03-16 재단법인대구경북과학기술원 무손실 세포 염색 방법 및 장치
EP4252725A3 (en) 2020-03-25 2023-11-22 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
AU2021269007A1 (en) 2020-05-04 2022-11-24 Ascendis Pharma A/S Hydrogel irradiation
CN113694261B (zh) * 2020-05-21 2022-09-09 江苏百赛飞生物科技有限公司 一种抗菌复合涂层及其制备方法和制品
US20210369651A1 (en) * 2020-05-28 2021-12-02 Sollievo Pharmaceuticals, Inc Parenteral delivery of avizafone
BR112022022826A2 (pt) 2020-06-03 2022-12-13 Ascendis Pharma Oncology Div A/S Sequências de il-2 e usos das mesmas
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
EP4192508A1 (en) 2020-08-05 2023-06-14 Ascendis Pharma A/S Conjugates comprising reversible linkers and uses thereof
IL300668A (en) 2020-08-28 2023-04-01 Ascendis Pharma Oncology Div A/S Glycosylated IL-2 proteins and their uses
US20230364199A1 (en) 2020-09-28 2023-11-16 Ascendis Pharma Bone Diseases A/S Improvement of physical and mental well-being of patients with hypoparathyroidism
CN112316156B (zh) * 2020-10-27 2022-03-15 四川大学 具抗氧化和抗菌性的胶原蛋白修复膜、其制备方法及应用
KR102437315B1 (ko) * 2020-11-02 2022-08-30 아주대학교산학협력단 하이브리드 하이드로겔 및 이의 생의학적 용도
WO2022207798A1 (en) 2021-04-01 2022-10-06 Ascendis Pharma A/S Use of long-acting growth hormone for treating inflammation-induced diseases
CN113304139B (zh) * 2021-06-30 2022-04-29 贵州医科大学 Viniferifuran在制备黄嘌呤氧化酶抑制药物中的应用
CN113398145B (zh) * 2021-07-02 2022-10-14 合肥康诺生物制药有限公司 含nad与氨氯地平的药物组合物及其用途
CN113461979A (zh) * 2021-07-19 2021-10-01 吉林大学 一种通过血红蛋白催化交联的仿贻贝类水凝胶的制备方法
WO2023110727A2 (en) 2021-12-13 2023-06-22 Ascendis Pharma Oncology Division A/S Novel cancer treatments with tlr7/8 agonists
CN114469926B (zh) * 2022-01-28 2023-06-27 吉林省健维天然生物科技有限公司 二氢槲皮素的新用途及二氢槲皮素水凝胶的制备方法
CN115109275B (zh) * 2022-08-29 2022-11-01 杭州艾名医学科技有限公司 一种动态交联可降解水凝胶、制备方法及应用
CN115444840B (zh) * 2022-09-15 2023-08-25 四川大学 一种前药、两性离子水凝胶及其制备方法、应用
CN115322397B (zh) * 2022-09-23 2024-04-30 福州大学 一种预防术后腹腔粘连的两性离子水凝胶及其制备方法
CN115537017B (zh) * 2022-09-27 2023-09-01 四川大学 一种水凝胶及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE197125T1 (de) 1992-02-28 2000-11-15 Univ Texas Photopolymerinierbare, biologisch abbaubare hydrogele als gewebekontaktmaterialien und trägerstoffe für kontrollierte freisetzung
US20020064546A1 (en) * 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
CA2479810A1 (en) 2002-04-04 2003-10-16 Enzon, Inc. Polymeric acyl derivatives of indoles
AU2003294369B2 (en) * 2003-01-17 2008-08-14 Cornell Research Foundation, Inc. Injectable hydrogel microspheres from aqueous two-phase system
AU2004228793B2 (en) 2003-04-08 2009-10-08 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
EP1626741A2 (en) * 2003-05-23 2006-02-22 Nektar Therapeutics Al, Corporation Peg derivatives having an amidocarbonate linkage
CA2786794C (en) * 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
US7968085B2 (en) * 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
DE102004051715A1 (de) 2004-10-23 2005-06-30 Clariant Gmbh Flüssigwaschmittel enthaltend Farbfixiermittel
KR100665672B1 (ko) * 2005-04-13 2007-01-09 성균관대학교산학협력단 새로운 온도 및 pH 민감성 블록 공중합체 및 이를 이용한고분자 하이드로겔
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8070810B2 (en) * 2006-01-12 2011-12-06 Histogenics Corporation Method for repair and reconstruction of ruptured ligaments or tendons and for treatment of ligament and tendon injuries
WO2008034122A2 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
GB0619175D0 (en) * 2006-09-29 2006-11-08 Univ Nottingham Polymer
EP2099845B1 (en) 2006-11-27 2020-12-23 Actamax Surgical Materials LLC Multi-functional polyalkylene oxides, hydrogels and tissue adhesives
CA2677532A1 (en) * 2007-02-06 2008-08-14 Incept, Llc Polymerization with precipitation of proteins for elution in physiological solution
US20080220047A1 (en) 2007-03-05 2008-09-11 Sawhney Amarpreet S Low-swelling biocompatible hydrogels
ES2381639T3 (es) 2007-04-13 2012-05-30 Kuros Biosurgery Ag Sellante polimérico para tejidos
LT2237799T (lt) 2008-02-01 2019-07-25 Ascendis Pharma A/S Provaistas, apimantis besiskaidantį linkerį
WO2009134336A1 (en) * 2008-04-28 2009-11-05 Zogenix, Inc. Novel formulations for treatment of migraine
CA2776723C (en) * 2009-10-29 2018-09-25 Ascendis Pharma As Sterilization of biodegradable hydrogels
EP2438930A1 (en) * 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate

Also Published As

Publication number Publication date
AU2010277556A1 (en) 2012-02-02
KR101770844B1 (ko) 2017-08-23
HRP20201609T1 (hr) 2021-01-08
MX2012001061A (es) 2012-03-26
NZ597960A (en) 2013-07-26
HUE052816T2 (hu) 2021-05-28
ZA201200686B (en) 2012-10-31
PL2459220T3 (pl) 2021-03-08
SG177761A1 (en) 2012-03-29
RU2554854C9 (ru) 2017-02-03
BR112012002280B1 (pt) 2020-04-07
ES2833035T3 (es) 2021-06-14
RU2554854C2 (ru) 2015-06-27
RU2012107137A (ru) 2013-09-10
CN102573913B (zh) 2014-06-18
JP5904941B2 (ja) 2016-04-20
CA2769162C (en) 2017-12-05
HK1173082A1 (en) 2013-05-10
CA2769162A1 (en) 2011-02-03
WO2011012715A1 (en) 2011-02-03
MX343925B (es) 2016-11-29
MY156872A (en) 2016-04-15
EP3782649A1 (en) 2021-02-24
JP2013500950A (ja) 2013-01-10
CN102573913A (zh) 2012-07-11
KR20120090039A (ko) 2012-08-16
IL217743A0 (en) 2012-03-29
EP2459220A1 (en) 2012-06-06
IL217743A (en) 2017-01-31
EP2459220B1 (en) 2020-09-09
US20120156259A1 (en) 2012-06-21
AU2010277556B2 (en) 2014-10-09
BR112012002280A2 (pt) 2016-06-14
US11559482B2 (en) 2023-01-24
LT2459220T (lt) 2020-12-28

Similar Documents

Publication Publication Date Title
HK1173082A1 (en) Biodegradable polyethylene glycol based water-insoluble hydrogels
HK1176311A1 (zh) 可生物降解水凝膠的消毒
EP2411440A4 (en) IMPROVED BIODEGRADABLE POLYMERS
IL217881A0 (en) Polymer compositions
IL226526A0 (en) A purposeful formulation for extinguishing fires
GB2488811B (en) Biodegradable polymer blend
EP2626386A4 (en) BIODEGRADABLE RESIN COMPOSITION
EP2534203A4 (en) THERMOPLASTIC POLYURETHANE-BLOCK COPOLYMER COMPOSITIONS
EP2443185A4 (en) POLYMER FOAMS
PL2516478T3 (pl) Modyfikowane kompozycje polimerowe
EP2393585A4 (en) POLYMER CASE
PL2516474T3 (pl) Modyfikowane kompozycje polimerowe
EP2498835A4 (en) BIODEGRADABLE THERMOPLASTIC ELASTOMERS
IL225892A0 (en) Formulations containing polyethylene glycol
GB201011029D0 (en) Plastic container
EP2556079A4 (en) POLYOLED MODIFIED AMINOGLYCOSIDE LIPID CONJUGATES
EP2446681A4 (en) MOBILE QUICK-ALARM
GB0922354D0 (en) Novel polymer conjugates
EP2391665A4 (en) POLYMER AND COMPOSITIONS POLYMER-NANOPARTICLE
HK1129990A2 (en) Surgical station
GB0914692D0 (en) Cross-link polymers
ZA201304053B (en) Formulations comprising polyethylene glycol
PT2395047T (pt) Polímeros biodegradáveis
TWM387075U (en) Biodegradable container for repast
PL387069A1 (pl) Biodegradowalny środek antyadhezyjny